as of March 11, 2015

# Wednesday, March 25

TIME	SESSION #	SESSION	COURSE DIRECTOR(S)	NOTES	CREDITS
7:00am – 5:00pm	221	Integrated Hemodialysis/Peritoneal Dialysis	Joanne Bargman, MD, FRCPC	• + 101	8.0 (2.5 Pharm)
7:30am – 5:15pm	220	Kidney Transplantation 2015	Fuad Shihab, MD, FNKF Milagros Samaniego, MD	• + 101	7.75 (2.0 Pharm)
7:30am – 4:30pm	222	CKD Management Along the Continuum: From Predialysis to Policy Supported by an educational grant from AstraZeneca	Charmaine Lok, MD, MSc, FNKF Christopher Chan, MD, FRCPC	• <b>* 10</b> 1	7.3 (0.3 Pharm)
7:30am – 12:00pm	620	Basics of Hemodialysis	Beverly Kimball, PA-C Kim Deaver, RN, MSN, CNN	• 101	3.75 (0.17 Pharm)
7:30am – 12:30pm	621	Critical Care in Nephrology – Part 1	Mandy Trolinger, MS, RD, PA-C, FNKF	• 101	4.25 (1.3 Pharm)
8:00am – 6:00pm	223	Glomerular Diseases: Updates on Pathogenesis and Treatment	Fernando Fervenza, MD, PhD, FNKF Michael Choi, MD, FNKF	• <b>†</b>	8.5 (3.6 Pharm)
12:30pm – 5:00pm	622	Basics of Peritoneal Dialysis	Beverly Kimball, PA-C Kim Deaver, RN, MSN, CNN	• 101	3.75
12:30pm – 5:30pm	623	Basics of Chronic Kidney Disease	Joanne Hindlet, ACNP, BC, CNN- NP	• 101	4.0 (0.6 Pharm)
1:00pm – 6:00pm	624	Critical Care in Nephrology – Part 2	Mandy Trolinger, MS, RD, PA-C, FNKF	• 101	4.25 (1.5 Pharm)
6:30pm – 7:30pm	101	Healthcare Professionals Welcome Reception		Ĭ	

# Thursday, March 26

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am	800	Breakfast Symposium: Hyperkalemia and Emerging Treatments in Chronic Kidney Disease Supported by an educational grant from ZS Pharma	Chair: Csaba Kovesdy, MD	101	1.5 (0.37 Pharm)
		Clinical Settings of Hyperkalemia	Csaba Kovesdy, MD	_	1.5 (0.25 Pharm)  1.5 (0.33 Pharm)  1.5 (0.25 Pharm)  1.5 (1.5
		Limitations in the Acute and Chronic Treatment of Hyperkalemia	Jerry Yee, MD, FNKF	_	
		Emerging Treatment Options for Hyperkalemia	Wolfgang Winkelmayer, MD, ScD, MPH, FASN		
6:00am – 7:45am	801	Breakfast Symposium: Getting Ahead of Metabolic and Mineral Disturbances in the Management of CKD-MBD: A Focus on Management Strategies Supported by an educational grant from sanofi-aventis U.S.	Chair: Ellie Kelepouris, MD, FAHA	† <b>©</b> }	(0.25
		Pathophysiology of CKD-MBD and Cardiovascular Consequences	Rajnish Mehrotra, MD, FNKF	-	
		Assessment of Dietary Interventions to Mitigate Risk	Kathleen Hill Gallant, PhD, RD, CD		
		Medical Management of Altered Calcium and Phosphorus in the Patient with CKD-MBD	Ellie Kelepouris, MD, FAHA		
8:00am – 9:30am	660	Understanding the Urinalysis			1.5
		Interpretation of the Urinalysis	Denise Link, MPAS, PA-C	_	(0.33
		Diagnosis and Treatment of Proteinuric Diseases	Robert Toto, MD	_	Pharm)
8:00am – 9:30am	661	Understanding Rheumatology			1.5
		Making sense of Rheumatology Labs	Janie McDaniel, BSMT		(0.25
		The Impact of Vasculitis	Ramesh Saxena, MD		Pharm)
9:30am – 10:00am		Break			
10:00am – 11:30am	662	Difficult-to-Treat Hypertension		_	1.5 (0.33 Pharm) 1.5 (0.25 Pharm)
		Multi-Drug Resistant Hypertension	Debbie Cohen, MD	_	•
		Case Studies in Difficult to Treat Hypertension	Raymond Townsend, MD, FAHA		1.5 (0.25 Pharm) 1.5 (0.33 Pharm) 1.5 (0.25 Pharm)

as of March 11, 2015

10:00am – 11:30am	663	Where Is the Lyte?			1.5
		Diuretic Resistance	Kamalanathan Sambandam, MD		(0.5
		Sodium Disorders	Biff Palmer, MD		pharm)
10:00am – 11:30am	288	Pursuit of High Value Care for Persons with Kidney Diseases	Shari Ling, MD	<b>+</b> +	1.5
11:30am – 12:00pm		Break			
12:00pm – 2:00pm	664	Council of Advanced Practitioners Networking Luncheon – All are Welcome!			
12:00pm – 2:00pm	802	Lunch Symposium: What Clinicians Need to Know About How Biosimilars Will Change the Treatment of Chronic Kidney Disease Supported by an educational grant from Hospira	Chair: Jay Wish, MD	<b>†©</b> 1	1.5 (0.42 Pharm)
		Biosimilars Regulation and Development in the United States	Edward Li, PharmD		
		Treating Anemia with Biosimilars: Exploring Risks and Benefits	Francesco Locatelli, MD		
		Operationalizing the Use of Biosimilar ESAs in the U.S.	Jay Wish, MD		
2:00pm – 2:30pm		Break			
2:30pm – 3:30pm	265	NKF Presidential Address: Improving CKD Patient Health  - We Have to Do Betterand We Can	Jeffrey Berns, MD, FNKF	++	1.0 (0.17
		Shaul G. Massry Distinguished Lecture: The Anion Gap – An Enduring Concept: 1923 to 2015	Michael Emmett, MD, MACP		Pharm)
3:30pm – 4:00pm		Break			
4:00pm – 5:30pm	665	To Dose Or Not to Dose			1.5
		Top 10 Nephrotoxic Drugs	Amy Barton Pai, PharmD, BCPS, FASN, FCCP		(1.3 Pharm)
		Drug Controversies in CKD	Cheryl Gilmartin, PharmD		
4:00pm – 5:30pm	267	What's New with KDOQI®?	Chair: Michael Rocco, MD	<b>*</b>	1.5
		2014 KDOQI Hemodialysis Adequacy Update	Thomas Depner, MD		
		How to Write a Hemodiafiltration Prescription and How to Monitor Therapy	Raymond Vanholder, MD		
		The KDOQI Nutrition Update: A Unique Partnership with the American Academy of Nutrition and Dietetics	T. Alp Ikizler, MD		
		A Multidisciplinary KDOQI Vascular Access Update	Charmaine Lok, MD, MSc, FNKF		
6:00pm – 7:30pm		Opening Ceremonies and Reception in the Exhibit Hall – Visit Posters/Exhibits		T	1.0*
7:30pm – 9:30pm	803	Dinner Symposium: Iron-Based Phosphate Binders: Clinical Implications of Novel Therapy Supported by an educational grant from Keryx Biopharmaceuticals, Inc.	Chair: Kevin Martin, MB, BCh, FACP	101	1.5 (0.67 Pharm)
		Hyperphosphatemia and the Failing Kidney	Kevin Martin, MB, BCh, FACP		
		Phosphate Binders in Hemodialysis	Diana Jalal, MD		
		Benefits Beyond? Ferric Citrate and Anemia Management in ESRD: Newest Evidence	Kausik Umanath, MD		
		Case Study: Challenges in Management of Hyperphosphatemia	All Faculty		
7:30pm – 9:30pm	804	Dinner Symposium: Utilizing Alternative Approaches to Achieve Uric Acid Target Levels Across a Multidisciplinary Team Supported by an educational grant from Takeda	Chair: Jay Wish, MD	101	1.5 (0.17 Pharm)
		Physiologic Basis for Hyperuricemic Gout and the Kidney's Role	Jay Wish, MD		
		Is There a Role for Screening for Hyperuricemia in Acute Kidney Injury and Chronic Kidney Disease?	A. Ahsan Ejaz, MD, FACP		
		Management of Acute Goat and Chronic Hyperuricemia	Robert Wortmann, MD		

as of March 11, 2015

Friday, March 27

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am	805	Breakfast Symposium: Nephropathic Cystinosis: New Insights and Approaches to Care Supported by an educational grant from Raptor Pharmaceuticals	Chair: Paul Goodyer, MD	101	1.5 (0.16 Pharm)
		New Insights into Pathogenesis and Diagnosis	Minnie Sarwal, MD, MRCP, FRCP, DCH, PhD		
		New Approaches to Treatment and Monitoring	Paul Goodyer, MD		
		Transitioning to Adolescent and Adult Care	Sandra Amaral, MD, MHS		
6:00am – 7:45am	1	Breakfast Symposium: Evolving Management of Hyperphosphatemia in Chronic Kidney Disease Supported by an educational grant from Fresenius Medical Care Renal Therapies Group	Chair: Daniel Coyne, MD		1.5
		Clinical Obstacles to Controlling Hyperphosphatemi	Stuart Sprague, DO	•	
		Refinement of Dietary Phosphate Restriction	Orlando Gutierrez, MD, MMSc	•	(0.16 Pharm)  1.0*  1.0*  1.5 (0.67 Pharm)  1.5 (0.17 Pharm)  1.5 (0.58 Pharm)  1.0*  1.5 (0.25 Pharm)  1.5 (0.25 Pharm)  1.5 (0.58 Pharm)
		Evolution of Phosphate Binders	Daniel Coyne, MD	•	
7:00am – 8:00am		Continental Breakfast in the Exhibit Hall – Visit Posters/Exhibits		101	1.0*
8:30am – 10:00am	566	Both Sides of Diabetes		+	1.5
		What Can I Eat on a Renal Diabetic Diet?	Marion Franz, RD		
		Medical management of Diabetes	Christine Kessler, NP	•	Pharm)
8:30am – 10:00am	666	The Path of Polycystic Kidney Disease	·		1.5
		Polycystic Kidney Disease	Benjamin Cowley, MD	•	
		Radiology of Cysts	Alexis Harris, MD	•	Pharm)
8:30am – 10:00am	268	What's New in Peritoneal Dialysis	Chairs: Joni Hansson, MD, FNKF, and Fredric Finkelstein, MD, FNKF	•	1.5
		PD Catheters: Who, Where, When, How and Outcomes	Robert Quinn, MD	•	
		Cycler Therapy: The Good, the Bad and What's New	Rajnish Mehrotra, MD, MBBS, FNKF	•	
		Timing of PD Initiation and Incremental PD	Joni Hansson, MD, FNKF	•	
10:00am – 10:30am		Break			
10:30am – 12:00pm	667	The Nervous Gut			1.5
·		Neurological Conditions in CKD	Dana Kumjian, MD	•	(0.58
		GI Issues in CKD	Jane Davis, DNP, CRNP, MSN, FNKF	•	Pharm)
10:30am – 12:00pm	668	Pregnancy and CKD			1.5
·		Impact of Pregnancy on CKD	Mandy Trolinger, MS, RD, PA-C, FNKF	•	(0.17
		Case Studies in Pregnancy and CKD	Kim Zuber, PA-C, FNKF	•	Pharm)
12:00pm – 2:00pm		Break in the Exhibit Hall (Lunch Served 12:15pm – 1:15pm) – Visit Posters/Exhibits		101	1.0*
2:00pm – 3:30pm	669	Hemodialysis Access: From Start to Finish			1.5
		Placement and Examination	Darlene Dobkowski, PA-C		
		Complications and Interventions	John Rundback, MD		
2:00pm – 3:30pm	670	Identifying Glomerulonephritis			1.5
		What is that GN?	Kamalanathan Sambandam, MD	•	(0.25
		Pathology and Case Studies	Alexis Harris, MD	•	Pharm)
2:00pm – 3:30pm	572	Dental Health and How It Affects Nutritional Status	Darlene West	+	1.5
		in Dialysis Patients	Cheryl Thomas, RD		
3:30pm – 4:00pm		Break			
4:00pm – 5:30pm	671	Research Update			1.5
		Top 10 Research Articles	Peter Juergensen, PA-C		(0.58
1.00рт 3.30рт				_	\
1.00рт 3.30рт		Update on Diabetic Nephropathy	Robert Toto, MD		Pharm)
	672	Update on Diabetic Nephropathy	Robert Toto, MD		Pharm,
4:00pm – 5:30pm	672		Robert Toto, MD  Harvey Feldman, MD, FACP		· · · · · · · · · · · · · · · · · · ·

as of March 11, 2015

4:00pm – 5:30pm	575	The ESRD Core Survey: Working Together to Improve Care	Judith Kari, MSSW Kelly Frank, RN, BSN Joe Messana, MD Teri Spencer, RN	+	1.5
5:30pm – 7:00pm		Networking Reception in the Exhibit Hall – Visit Posters/Exhibits		T	1.0*
7:00pm – 9:00pm	807	Dinner Symposium: Simplifying the Algorithm: Diagnosis and Treatment of Hyponatremias Supported by an educational grant from Otsuka America Pharmaceutical, Inc.	Chair: Biff Palmer, MD	101	1.5 (0.25 Pharm)
		Hypotonic Hyponatremias: Pathophysiologies	Tomas Berl, MD	•	
		Managing Hyponatremia: Simplifying the Therapeutic Algorithm	Richard Sterns, MD	•	
		Managing Hyponatremia: The Role of Vasopressin Antagonists	Biff Palmer, MD	•	
		Case Study: Managing Hyponatremia in a Patient with SIADH	All Faculty	•	
7:00pm – 9:00pm	808	Dinner Symposium: The Potassium Challenge in CKD: Managing Acute and Chronic Hyperkalemia Supported by an educational grant from Relypsa	Chair: Robert Toto, MD	101	1.5 (0.25 Pharm)
		Hyperkalemia in CKD: A Clinical Conundrum	Robert Toto, MD	-	
		Novel Potassium Binders: Clinical Evidence	Peter McCullough, MD, MPH, FACC, FACP, FAHA, FCCP, FNKF	-	
		Case Study: Managing Chronic Hyperkalemia in a Patient with CKD and Cardiovascular Disease	Kamyar Kalantar-Zadeh, MD, PhD, MPH, FNKF	-	

Saturday, March 28

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
7:15am – 9:00am	809	Breakfast Symposium: Pathogenesis and Management of Nephrotic Syndrome in Primary Podocytopathies Supported in part by an educational grant from Mallinckrodt Pharmaceuticals	Chair: Fernando Fervenza, MD, PhD, FNKF	<b>†©</b>	1.5 (0.33 Pharm)
		Insights Regarding the Pathogenesis and Evaluation of Nephrotic Syndrome	Laurence Beck, Jr., MD, PhD		
		Management of Nephrotic Syndrome: Treatment Strategies and Current Treatment Options	Brad Rovin, MD		
		A Case-Based Approach to Management of Nephrotic Syndrome	Fernando Fervenza, MD, PhD, FNKF		
8:00am – 11:30am		Break in the Exhibit Hall (Breakfast Served 8:00am – 9:00am) – Visit Posters/Exhibits		101	1.0*
9:30am – 11:00am	276	KEEP Healthy™: Insights into CKD Care	Chairs: Kerri Cavanaugh, MD, FNKF, and Josef Coresh, MD, PhD, MHS	•	1.5
		Awareness and the Continued Need for CKD Detection	Beth Piraino, MD, FNKF	•	
		Evolution of the KEEP into KEEP Healthy	Peter McCullough, MD, FNKF	•	
		Insights into KEEP Healthy	Kerri Cavanaugh, MD, FNKF	•	
9:30am – 11:00am	673	Transplantation: From Start to Finish			1.5
		The Work Up	Erin Carrithers, NP		(0.67
		Management and Complications	Barbara Weis Malone, MSN, RN, CFNP, FNKF		Pharm)
11:00am – 11:30am		Break			
11:30am – 12:30pm	674	Weight Management Interventions	Beth Evans, RN, MSN, DNP		1.0 (0.17 Pharm)

as of March 11, 2015

11:30am – 1:00pm	235	Lunch Workshop: Evaluation and Management of Depression and Anxiety in CKD	Chair: Fredric Finkelstein, MD, FNKF	• + 101	1.5 (0.17
		Overview of Depression and Anxiety in CKD	Fredric Finkelstein, MD, FNKF		Pharm)
		Diagnosis and Treatment of Depression and Anxiety in CKD	Susan Hedayati, MD	•	
		Addressing Depression and Anxiety to Improve Patient Experience	Rajnish Mehrotra, MD, MBBS, FNKF	•	
11:30am – 1:00pm	236	Lunch Workshop: Pregnancy Care in CKD	Chairs: Susan Furth, MD, PhD, FNKF, and Debbie Cohen, MD	• + 101	1.5 (0.17
		Preserving Fertility in Teens and Young Adults with Kidney Disease	Wendy Vitek, MD	•	Pharm)
		Hypertension and Pregnancy (more than just preeclamsia)	Vesna Garovic, MD	•	(0.17 Pharm) 1.5 (0.17
		Management of the Pregnant Patient with CKD/ESRD	Michelle Hladunwich, MD		
11:30am – 1:00pm	237	<b>Lunch Workshop: Acid-Base and Electrolytes</b> Supported by an educational grant from ZS Pharma	Chair: Lawrence Weisberg, MD, FNKF, FASN, FACP	• + 101	
		Cases	Biff Palmer, MD	•	1.5 (0.17 Pharm)  1.5 (0.5 Pharm)  1.5  1.5 (0.33
		Cases	Lawrence Weisberg, MD, FNKF, FASN, FACP	•	
		Cases	Michael Emmett, MD		
11:30am – 1:00pm	238	Lunch Workshop: Challenges in PD	Chairs: Joel Glickman, MD, and Joni Hansson, MD, FNKF	• • 101	1.5
		Diagnosis and Management of Ultrafiltration Failure	Joanne Bargman, MD, FRCPC		
		EPS: What to You Discuss with Your Long-Term PD Patients?	Joni Hansson, MD, FNKF	•	
		PD Adequacy: What Formula - What V?	Joel Glickman, MD	•	
11:30am – 1:00pm	239	Lunch Workshop: The "Difficult Patient" on Hemodialysis	Chairs: Raymond Vanholder, MD	• + 101	1.5
		Managing the "Difficult Dialysis Patient:" Ethical Foundations	Richard Goldman, MD	•	
		The Medical Director's Responsibilities Regarding "Difficult Dialysis Patients"	Jeffrey Perlmutter, MD	•	
		Nonadherence to the Dialysis Prescription: Truth and Consequences	Charlonda Thrower, LMSW	•	
11:30am – 1:00pm	240	Lunch Workshop: Onco-Nephrology: Myeloma, Primary Amyloidosis, and Other Monoclonal Deposition Diseases	Chair: Fernando Fervenza, MD, PhD, FNKF	• + 101	1.5
		Overview of Paraproteinemic Kidney Diseases	Paul Sanders, MD	•	
		Prognosis and Treatment for Myeloma and Amyloid	Laura Dember, MD	•	
		Case Presentations	Agnes Fogo, MD	•	
1:00pm – 1:30pm		Break			
1:30pm – 3:00pm	675	The Heart of the Matter			1.5
		Cardiovascular Disease	Peter McCullough, MD, FNKF	•	
		Peripheral Arterial Disease	Darlene Dobkowski, PA-C	•	Pharm)
1:30pm – 3:00pm	676	The Cost of Infections			
		Common Infections in CKD Patients	Beth Adams, PA-C		
		Preventing Hospital Readmissions	Debra Hain, PhD, APRN, ANP, GNP- BC		Pharm)
1:30pm – 3:00pm	279	Biosimilars and Other "Similars" in Nephrology: Setting the Course for Uncharted Territories	Chair: Amy Barton Pai, PharmD, BCPS, FASN, FCCP	•	
		Biosimilar ESAS: How Dissimilar are They?	Jay Wish, MD	-	Pharm)
		Generic IV Iron Forumulations: Black Solutions in a	Amy Barton Pai, PharmD, BCPS,		
		Regulatory Gray Area	FASN, FCCP		
		Time for a New Direction? Pipeline Agents for Treating Anemia of CKD	Daniel Coyne, MD	-	

as of March 11, 2015

3:30pm – 5:00pm	677	Blood Cells Gone Bad			1.5
		Paraproteinemias	TBD		(0.42
		Common Hematological Conditions	Lindsey Lyle, PA-C		Pharm)
3:30pm – 5:00pm	678	Importance of the Heart and Liver on the Kidneys			1.5
		Cardiorenal	Peter Juergensen, PA-C		(0.42 Pharm)
		Hepatorenal	Catherine Wells, DNP, ACNP-BC,		Pharm)
			CNN-NP, FNKF		
3:30pm – 5:00pm	281	Volume First: Is It About Time?	Chairs: Steven Brunelli, MD	•	1.5
		Consequences of Volume Overload in patients on Hemodialysis and Weight Gain/Time Conundrum	Steven Brunelli, MD	_	
		Relationship of BP Control and Volume	Rajiv Agrawal, MD	_	
		Tools for Assessing Volume Status in Patients on Hemodialysis	Mitch Rosner, MD	_	

Sunday, March 29

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
8:00am – 9:30am 284	284	BP Monitoring and Management	Chairs: Mahboob Rahman, MD, and Rajiv Agarwal, MD	•	1.5 (0.42
		What is the Role of ABPM and Home Blood Pressure Monitoring in CKD	Mahboob Rahman, MD	_	Pharm)
	When is the Best Time to Measure BP in a Dialysis Patient?	Rajiv Agarwal, MD	_		
		Medication Management of BP in Hemodialysis Patients: Is 3x a Week Dosing Appropriate?	Rajiv Agarwal, MD	-	
8:00am – 9:30am	679	Depression and Pain Management			1.5
		Depression and CKD	Fredric Finkelstein, MD, FNKF		(0.67
		Pain Management	Aaron Van Wright, MD		Pharm)
9:30am – 10:00am		Break		-	
10:00am – 11:30am	680	Update on Bone and Mineral Management			1.5
		Update on Bone and Mineral Disease	Geoffrey Block, MD, CCRI	_	(0.67
		Calcium Dilemmas	Christine Kessler, MSN, ANP		Pharm)
10:00am – 11:30am	287	What the Nephrologist Needs to Know About Under- recognized Endocrine Disorders in CKD	Chairs: David Salant, MD, and Daniel Weiner, MD, MS, FNKF	•	1.5
		The Thyroid-Kidney Interaction and its Impact on CKD Outcomes	Connie Rhee, MD	,	
		Testosterone Deficiency, Clinical Outcomes, and Management in CKD	Kirsten Johansen, MD		
		Fertility & Contraception	Muhammad Mustafa, MD		
11:30am		Meeting Adjourns			

- Additional registration/fee required
- ◆ Joint with Physicians
- **→** Joint with Councils
- T Cocktail Reception
- Meal served